Evolving Targeted Therapies for Cancer

Development of novel Radio, Chemo and Immunotherapies for Monotherapy and Combination Therapy Approaches to Treat Cancer

The goal of this workshop is to discuss the emerging use of targeted mono and combination therapies to treat cancer. This will be the third workshop in the Accelerating Radiotherapeutic Innovations and Applications (ARIA) series and will be a continuation of the workshop held in 2019. We will refocus on how targeted radiotherapies can be integrated into the evolving landscape of precision cancer treatments as monotherapies and combination therapies. This workshop will assess the use of novel chelators, nanotechnology and targeting vectors in the development of innovative targeted therapies for cancer and discuss the emerging use of targeted radiotherapy, chemotherapy and immunotherapy to treat disease. Assessing the impact of these therapies at the molecular and cellular level is crucial to the development of effective treatments that maximize tumor cell killing while minimizing impact to normal cells, tissue, and organs. Therefore, a key element of this workshop is understanding the radiobiology and dosimetry of these targeted radiotherapies and assessing in vitro and in vivo models to facilitate translation into effective patient treatments.

This workshop will help address the following:

1. Determine the potential of new chelators and nanotechnology for enhancing targeted radiotherapies
2. Evaluate the radiobiology and dosimetry of targeted radiotherapies
3. Examine the potential for combination chemotherapy, radiotherapy and immunotherapy to enhance tumor cell killing and eradication

Submit an Abstract